Zacks Small Cap Analysis – XFOR: First Business Gross sales of XOLREMDI… – Go Well being Professional
By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Monetary Replace On August 8, 2024, X4 Prescription drugs, Inc. (NASDAQ:XFOR) introduced monetary outcomes for the second quarter of 2024. The corporate recorded the primary revenues for XOLREMDI following its industrial launch in April 2024. Income within the second quarter of 2024 totaled $0.6 … Read more
